The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience
- PMID: 37701381
- PMCID: PMC10495054
- DOI: 10.53854/liim-3103-5
The sources of antimicrobial peptides against Gram-positives and Gramnegatives: our research experience
Abstract
Antibiotic resistance of Gram-positive and Gramnegative bacteria is becoming increasingly prevalent. For this reason, the search for new molecules that can overcome current resistance and also recover antibiotics that are no longer effective is becoming increasingly urgent. Our research group at the 'Polytechnic University of Marche' managed to study the effectiveness of certain antimicrobial peptides (AMPs). We decided to review our experience with AMPs by classifying them according to their origin and evaluating their effect on Gram-negative and Gram-positive bacteria. AMPs can derive from mammals, amphibians, microorganisms, and insects. In conclusion, our research experience shows that the richest source of AMPs are amphibians. However, the studies done are mainly in vitro or in animal models, requiring further human studies to assess the efficacy and safety of these molecules. AMPs may be a new therapeutic option for infections sustained by multi-resistant micro-organisms and for overcoming the mechanisms of resistance to antibiotics currently used. In particular, combining AMPs with antibiotics, including those with limited antimicrobial activity due to antimicrobial resistance, has often shown a synergistic effect, increasing or restoring their efficacy. The possibility of using manageable and relatively safe antibiotics again is crucial, considering the widespread increase in bacterial resistance in hospitals and the community. Despite a plethora of research on AMPs and their application as potential treatment on infectious diseases, this area needs further exploration. There is evidence that the characteristics of AMPs can seriously improve through structural chemical modifications and different delivery systems to become alternatives drugs to conventional antibiotics. The aim is to provide an overview of the possible sources from which AMPs are extracted, evaluating their action exclusively on Gram-positive and negative bacteria. This is to determine, based on our experience, which might be the most promising sources of AMPs for future research as well.
Keywords: AMPs; Gram negative bacteria; Gram positive bacteria; antibiotic resistance.
Conflict of interest statement
Conflict of interest disclosures The authors have no competing interests to declare.
Similar articles
-
Our Experience over 20 Years: Antimicrobial Peptides against Gram Positives, Gram Negatives, and Fungi.Pharmaceutics. 2022 Dec 22;15(1):40. doi: 10.3390/pharmaceutics15010040. Pharmaceutics. 2022. PMID: 36678669 Free PMC article. Review.
-
Ab initio Designed Antimicrobial Peptides Against Gram-Negative Bacteria.Front Microbiol. 2021 Nov 16;12:715246. doi: 10.3389/fmicb.2021.715246. eCollection 2021. Front Microbiol. 2021. PMID: 34867843 Free PMC article.
-
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?Front Cell Infect Microbiol. 2019 Apr 30;9:128. doi: 10.3389/fcimb.2019.00128. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31114762 Free PMC article.
-
Functional synergy of α-helical antimicrobial peptides and traditional antibiotics against Gram-negative and Gram-positive bacteria in vitro and in vivo.Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):197-204. doi: 10.1007/s10096-014-2219-3. Epub 2014 Aug 30. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25169965
-
How to Combat Gram-Negative Bacteria Using Antimicrobial Peptides: A Challenge or an Unattainable Goal?Antibiotics (Basel). 2021 Dec 7;10(12):1499. doi: 10.3390/antibiotics10121499. Antibiotics (Basel). 2021. PMID: 34943713 Free PMC article. Review.
References
-
- Simonetti O, Silvestri C, Arzeni D, et al. In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes. Mycoses. 2014;57(4):233–239. - PubMed
-
- Kamysz E, Simonetti O, Cirioni O, et al. In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp. Peptides. 2011;32(1):99–103. - PubMed
-
- Barchiesi F, Silvestri C, Arzeni D, et al. In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. Med Mycol. 2009;47(3):321–326. - PubMed
Publication types
LinkOut - more resources
Full Text Sources